Anthera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for patients with unmet medical needs. It develops Sollpura, a non-porcine investigational pancreatic enzyme replacement therapy that is in Phase III clinical trial for the treatment of patients with exocrine pancreatic insufficiency; and Blisibimod, which is in Phase II clinical trial for the treatment of B-cell mediated autoimmune diseases, including immunoglobulin A nephropathy or IgA nephropathy. The company has license agreements with Amgen, Inc., and Eli Lilly and Company. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

Receive ANTH News and Ratings via Email

Sign-up to receive the latest news and ratings for ANTH and its competitors with MarketBeat's FREE daily newsletter.

Miscellaneous

Anthera Pharmaceuticals (NASDAQ:ANTH) Frequently Asked Questions

What is Anthera Pharmaceuticals' stock symbol?

Anthera Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANTH."

When did Anthera Pharmaceuticals' stock split? How did Anthera Pharmaceuticals' stock split work?

Anthera Pharmaceuticals's stock reverse split on the morning of Monday, May 1st 2017. The 1-8 reverse split was announced on Friday, April 28th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 28th 2017. An investor that had 100 shares of Anthera Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

When is Anthera Pharmaceuticals' next earnings date?

What price target have analysts set for ANTH?

4 brokerages have issued 1 year target prices for Anthera Pharmaceuticals' shares. Their forecasts range from $0.50 to $10.00. On average, they expect Anthera Pharmaceuticals' share price to reach $5.25 in the next twelve months. This suggests a possible upside of 8,650.0% from the stock's current price. View Analyst Price Targets for Anthera Pharmaceuticals.

What is the consensus analysts' recommendation for Anthera Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anthera Pharmaceuticals in the last year. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Anthera Pharmaceuticals.

Has Anthera Pharmaceuticals been receiving favorable news coverage?

Press coverage about ANTH stock has been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Anthera Pharmaceuticals earned a news sentiment score of 0.9 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the immediate future.

How do I buy shares of Anthera Pharmaceuticals?

Shares of ANTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Anthera Pharmaceuticals' stock price today?

One share of ANTH stock can currently be purchased for approximately $0.06.

MarketBeat Community Rating for Anthera Pharmaceuticals (NASDAQ ANTH)

MarketBeat's community ratings are surveys of what our community members think about Anthera Pharmaceuticals and other stocks. Vote "Outperform" if you believe ANTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANTH will underperform the S&P 500 over the long term. You may vote once every thirty days.